Abstract:To investigate the antitumor activity and immunity enhancement of salidroside. The tumor model was established using subcutaneous BGC-823 cell injection in BALB/c mice, and the animals were divided into the salidroside treatment groups (high, middle and low concentration), and cyclophosphamide (CTX) treatment group was positive control as while saline treatment group was negative control. The mice bodies and tumors were weighted and the spleen coefficient was measured. Spleen lymphocyte conversion ratio and IL-2 activity were also measured. Comparing to negative control group, the mice body weight were significantly higher and the tumor weight were significantly lower in salidroside treatment groups, but the body weight markedly decreased in the group treated with CTX (P<0.05). And their thymus and spleen coefficient were higher than negative control groups. salidroside increased spleen lymphocyte conversion ratio and IL-2 value, but all the above value were significantly decreased in CTX treatment group. Salidroside can obviously inhibit BGC-823 tumor growth by increasing the body weight of mice, enhancing the immunity, which can improve the drug tolerance of patients.